A global population of patients with prediabetes that is three times the number of those with type 2 diabetes has led to intense competition between drug makers to treat the disease, according to a new report. The "Analysis of the Global Type 2 Diabetes Therapeutic Market" found that 15 new …

Research presented at the ADA Scientific Sessions showed the one-year drug discontinuation rate among type 2 diabetes patients was 89% in those taking a GLP-1 agonist, 82% in those who took a DPP-4 inhibitor and 84% in those treated with other diabetes drugs. The median time to treatment discontinuation was …

Improved economic conditions may have resulted in habits that led to diabetes, according to a study that examined the connection between the prevalence of diabetes and state-based per-capita income growth from 1950 to 1980. Children whose parents were previously poor were not biologically ready to handle the sedentary lifestyle and …

Sugar intake seems to promote the growth and spread of tumors in fruit flies through a few pathways….

High intensity physical activity in sessions less than 10 minutes can be as effective for losing weight as lower intensity exercise over a longer period of time….

New information on one of diabetes’ most debilitating complications…. Diabetic neuropathy affects approximately 60-70% of people with diabetes. For such a common problem that affects patients with diabetes, little is known about peripheral neuropathy. Patients with diabetes who are suffering from peripheral neuropathy talk of how terrible it is to …

Elevation in oxidative stress level can damage cell and tissue….

This study systemically reviewed randomized controlled trials and observational studies to evaluate whether actual exposure of metformin can be associated with cancer and cancer mortality in type 2 diabetes patients….

Women diagnosed with Polycystic Ovary Syndrome are at an increased risk of type 2 diabetes and cardiovascular disease….

Promising results from IDegLira and the DUAL I trial…. Novo Nordisk’s new drug IDegLira is a fixed-ratio combination of insulin degludec and the glucagonlike perptide-1 (GLP-1) agonist liraglutide. It combines the effects of insulin degludec and liraglutide in a once daily injection. In the Dual Action of Liraglutide and Insulin …